-

Reginald Brown to Join Blackstone’s Board of Directors

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE:BX) today announced that Reginald (“Reg”) J. Brown, Partner at the international law firm WilmerHale, will join its board of directors.

Brown serves as chair of WilmerHale’s Financial Institutions Group, among other roles at the firm. He regularly advises companies in the financial services industry on a range of issues at the intersection of government, law, media and public policy, and provides strategic counsel to individuals and companies across other sectors as well. From 2003 to 2005 Brown served as associate White House Counsel and special assistant to the President and also previously worked as Assistant to the CEO and Vice President for Corporate Strategy at Nationwide Mutual Insurance Company.

Commenting on the appointment, Stephen A. Schwarzman, Blackstone Chairman, CEO and Co-Founder, said: “Over his career in the private and public sector, Reg has helped counsel some of the world largest companies and prominent political leaders. His experience across a range of industries and unique perspective will be invaluable as we continue to grow our business.”

Reg Brown said: “Blackstone’s rapid growth is a testament to the strength of its people and the stellar reputation it has earned among its investors. I look forward to joining the firm’s board and contributing to its continued success.”

Brown holds a BA from Yale University and a JD from Harvard Law School. Brown is a member of the Boards of the Foundation for Excellence in Education, the Property and Environment Research Center, the American Council on Germany and Service Year Alliance.

About Blackstone

Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $564 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

Contacts

Jennifer Friedman
+1 (212) 583-5122
Jennifer.Friedman@blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Jennifer Friedman
+1 (212) 583-5122
Jennifer.Friedman@blackstone.com

More News From Blackstone

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom